Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance

Diabetes

Volumn 63, Issue 11, 2014, Pages 3742-3747

  Henriksbo, Brandyn D ^a   Lau, Trevor C ^a   Cavallari, Joseph F ^a   Denou, Emmanuel ^a   Chi, Wendy ^a   Lally, James S ^b   Crane, Justin D ^b   Duggan, Brittany M ^a   Foley, Kevin P ^a   Fullerton, Morgan D ^a,b   Tarnopolsky, Mark A ^b   Steinberg, Gregory R ^a,b   Schertzer, Jonathan D ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CRYOPYRIN; FLUINDOSTATIN; GLIBENCLAMIDE; INSULIN; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROTEIN KINASE B; CARRIER PROTEIN; CIAS1 PROTEIN, MOUSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; INFLAMMASOME; MONOUNSATURATED FATTY ACID;

3T3 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; ENZYME INHIBITION; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; LONG TERM CARE; MACROPHAGE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM;

3T3-L1 CELLS; ADIPOSE TISSUE; ANIMALS; CARRIER PROTEINS; CASPASE 1; FATTY ACIDS, MONOUNSATURATED; GLYBURIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INFLAMMASOMES; INSULIN RESISTANCE; INTERLEUKIN-1BETA; MACROPHAGES; MALE; MICE; OBESITY;

EID: 84906870036     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1398     Document Type: Article

References (27)

1. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6:358-370
2. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011;29:415-445
3. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet 1999;353:983-984
4. Mandey SHL, Kuijk LM, Frenkel J, Waterham HR. A role for geranylgeranylation in interleukin-1b secretion. Arthritis Rheum 2006;54: 3690-3695
5. Liao Y-H, Lin Y-C, Tsao S-T, et al. HMG-CoA reductase inhibitors activate caspase-1 in human monocytes depending on ATP release and P2X7 activation. J Leukoc Biol 2013;93:289-299
6. Xu J-F, Washko GR, Nakahira K, et al.; COPDGene Investigators. Statins and pulmonary fibrosis: the potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med 2012;185:547-556
7. Wen H, Gris D, Lei Y, et al. Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 2011;12:408-415
8. Lee H-M, Kim J-J, Kim HJ, Shong M, Ku BJ, Jo E-K. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes 2013;62: 194-204
9. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012;172:144-152
10. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012;380:565-571
11. Lamkanfi M, Mueller JL, Vitari AC, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol 2009;187:61-70
12. Moriyama T, Kawada N, Nagatoya K, et al. Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 2001;59:2095-2103
13. Jorgensen SB, O'Neill HM, Sylow L, et al. Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity. Diabetes 2013;62:56-64
14. Schertzer JD, Tamrakar AK, Magalhães JG, et al. NOD1 activators link innate immunity to insulin resistance. Diabetes 2011;60:2206-2215
15. Bauernfeind FG, Horvath G, Stutz A, et al. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 2009;183:787-791
16. Stehlik C. Multiple interleukin-1b-converting enzymes contribute to inflammatory arthritis. Arthritis Rheum 2009;60:3524-3530
17. LaRosa JC, Grundy SM, Waters DD, et al.; Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-1435
18. Goldfine AB. Statins: is it really time to reassess benefits and risks? N Engl J Med 2012;366:1752-1755
19. Schroder K, Zhou R, Tschopp J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 2010;327:296-300
20. Montero MT, Hernández O, Suárez Y, et al. Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells. Atherosclerosis 2000;153:303-313
21. Tse FLS, Jaffe JM, Troendle A. Pharmacokinetics of fluvastatin after single and multiple doses in normal volunteers. J Clin Pharmacol 1992;32:630-638
22. Holstein SA, Knapp HR, Clamon GH, Murry DJ, Hohl RJ. Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies. Cancer Chemother Pharmacol 2006;57:155-164
23. Matteucci E, Giampietro O. Statin intolerance: why and what to do - with a focus on diabetic people. Curr Med Chem 2013;20:1397-1408
24. Stienstra R, Joosten LAB, Koenen T, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab 2010;12:593-605
25. Kesh SB, Sikder K, Manna K, et al. Promising role of ferulic acid, atorvastatin and their combination in ameliorating high fat diet-induced stress in mice. Life Sci 2013;92:938-949
26. Satoh M, Tabuchi T, Itoh T, Nakamura M. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin. Clin Sci (Lond) 2014;126: 233-241
27. Cani PD, Bibiloni R, Knauf C, et al. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 2008;57:1470-1481